Listed

Tempest Therapeutics, Inc.: Form 10-K for the period ended Dec 31, 2019

Filed with the SEC on Mar 11, 2020 and accepted by EDGAR at Mar 11, 2020, 06:39 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2019-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Operating income12 months2019-01-01 to 2019-12-31−$45.4mus-gaap:OperatingIncomeLoss
Net income12 months2019-01-01 to 2019-12-31−$44.6mus-gaap:NetIncomeLoss
Diluted EPS12 months2019-01-01 to 2019-12-31−$3.25us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow12 months2019-01-01 to 2019-12-31−$41.2mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure12 months2019-01-01 to 2019-12-31$397.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2019-12-31$62.5mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2019-12-31$71.1mus-gaap:AssetsCurrent
Total assetsAt period end2019-12-31$75.0mus-gaap:Assets
Current liabilitiesAt period end2019-12-31$12.5mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2019-12-31$15.1mus-gaap:Liabilities
Long-term debtAt period end2019-12-31$168.0kus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2019-12-31$208.0kus-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2019-12-31$58.5mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001544227-20-000004. Last ingested by Listed: Nov 15, 2026, 00:20 ET. Listed shows no prices and gives no investment advice.